Human C-FMS antibodies
Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-1, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages.
1. An isolated antibody or antibody fragment, wherein the antibody or antibody fragment binds human c-fms and comprises a CDRH1, a CDRH2, a CDRH3, a CDRL1, a CDRL2, and a CDRL3, wherein:
CDRH1 comprises SEQ ID NO:140, CDRH2 comprises SEQ ID NO:155, CDRH3 comprises SEQ ID NO:169, CDRL1 comprises SEQ ID NO:202, CDRL2 comprises SEQ ID NO:218, and CDRL3 comprises SEQ ID NO:236; or
CDRH1 comprises SEQ ID NO:140, CDRH2 comprises SEQ ID NO:155, CDRH3 comprises SEQ ID NO:169, CDRL1 comprises SEQ ID NO:201, CDRL2 comprises SEQ ID NO:218, and CDRL3 comprises SEQ ID NO:236.
2. The antibody or antibody fragment of claim 1 , wherein CDRH1 comprises SEQ ID NO:140, CDRH2 comprises SEQ ID NO:155, CDRH3 comprises SEQ ID NO:169, CDRL1 comprises SEQ ID NO:202, CDRL2 comprises SEQ ID NO:218, and CDRL3 comprises SEQ ID NO:236.
3. The antibody or antibody fragment of claim 1 , wherein CDRH1 comprises SEQ ID NO:140, CDRH2 comprises SEQ ID NO:155, CDRH3 comprises SEQ ID NO:169, CDRL1 comprises SEQ ID NO:201, CDRL2 comprises SEQ ID NO:218, and CDRL3 comprises SEQ ID NO:236.
4. An isolated antibody or antibody fragment, wherein the antibody or antibody fragment binds human c-fms and comprises a VH and a VL, wherein:
VH comprises SEQ ID NO:70 and VL comprises SEQ ID NO:102; or
VH comprises SEQ ID NO:70 and VL comprises SEQ ID NO:103.
5. The antibody or antibody fragment of claim 4 , wherein VH comprises SEQ ID NO:70 and VL comprises SEQ ID NO:102.
6. The antibody or antibody fragment of claim 4 , wherein VH comprises SEQ ID NO:70 and VL comprises SEQ ID NO:103.
7. An isolated antibody or antibody fragment, wherein the antibody or fragment comprises a full heavy chain and a full light chain, and wherein:
the full heavy chain comprises SEQ ID NO:4 and the full light chain comprises SEQ ID NO:36; or
the full heavy chain comprises SEQ ID NO:4 and the full light chain comprises SEQ ID NO:37.
8. The antibody or antibody fragment of claim 7 , wherein the full heavy chain comprises SEQ ID NO:4 and the full light chain comprises SEQ ID NO:36.
9. The antibody or antibody fragment of claim 7 , wherein the full heavy chain comprises SEQ ID NO:4 and the full light chain comprises SEQ ID NO:37.
10. The antibody or antibody fragment of any one of claims 1 - 3 , 4 - 6 , and 7 - 9 claim 1 that has one or more of the following characteristics:
(a) is a monoclonal antibody;
(b) is a chimeric, a humanized or a fully human antibody;
(c) is an antibody of the IgG1-, IgG2-, IgG3- or IgG4-type;
(d) is a Fab fragment, a Fab' fragment, an F(ab') 2 fragment, or an Fv fragment; and
(e) is labeled.